Media Articles Related to Ophthetic (Proparacaine Ophthalmic)
Wayne State research team issued patent for new anesthesia monitoring technology
Source: Pain / Anesthetics News From Medical News Today [2015.06.17]
A team of researchers from Wayne State University was recently issued a U.S.
General anesthesia in young children linked to poorer intelligence, language development
Source: Pain / Anesthetics News From Medical News Today [2015.06.08]
Children who undergo surgical anesthesia under the age of 4 may have poorer language development and a lower IQ, according to new research from Cincinnati Children's Hospital.
More Evidence That General Anesthesia May Affect Young Brains
Source: MedicineNet MRI Scan Specialty [2015.06.08]
Title: More Evidence That General Anesthesia May Affect Young Brains
Category: Health News
Created: 6/8/2015 12:00:00 AM
Last Editorial Review: 6/8/2015 12:00:00 AM
Surgery Patients Might Not Need Sedative Before Anesthesia
Source: MedicineNet lorazepam Specialty [2015.03.04]
Title: Surgery Patients Might Not Need Sedative Before Anesthesia
Category: Health News
Created: 3/3/2015 12:00:00 AM
Last Editorial Review: 3/4/2015 12:00:00 AM
For children with autism, trips to the dentist just got easier
Source: Dentistry News From Medical News Today [2015.05.14]
Adjusting the environment to be more soothing could eliminate the need for general anesthesia to cope with routine cleaningsGoing to the dentist might have just gotten a little less scary for the...
Published Studies Related to Ophthetic (Proparacaine Ophthalmic)
Dilute proparacaine for the management of acute corneal injuries in the emergency department. [2010.09]
OBJECTIVE: Dogma discourages the provision of topical anesthetics to patients with corneal injuries discharged from the emergency department because of the toxicity of concentrated solutions. We compared the analgesic efficacy of dilute topical proparacaine with placebo in emergency department patients with acute corneal injuries... CONCLUSION: Dilute topical proparacaine is an efficacious analgesic for acute corneal injuries. Although no adverse events were observed in our study population, larger studies are required to evaluate safety.
Subtenon lidocaine vs topical proparacaine in adult strabismus surgery. [2006.09]
Intraoperative subtenon 2% lidocaine and topical 0.5% proparacaine in patients undergoing strabismus surgery were compared. No additional systemic analgesics and sedatives were used.Topical 0.5% proparacaine may be preferred because of its easy administration and fewer side effects, lack of hospital admission, and immediate and predictable alignment of the eyes.
Duration of effect and effect of multiple doses of topical ophthalmic 0.5% proparacaine hydrochloride in clinically normal dogs. [2005.01]
OBJECTIVE: To determine the duration of effect and the effect of multiple doses of topical ophthalmic application of 0.5% proparacaine hydrochloride on corneal sensitivity in clinically normal dogs...
A randomised comparison of lidocaine 2% gel and proparacaine 0.5% eye drops in
paediatric squint surgery. 
We conducted a randomised trial comparing lidocaine 2% gel with proparacaine 0.5%
eye drops in children having elective squint surgery. One hundred and forty
children aged between 3 and 14 years were recruited... We conclude that, compared with proparacaine 0.5% eye drops,
a single application of lidocaine 2% gel improves peri-operative analgesia and
reduces the incidence of postoperative nausea and vomiting in elective paediatric
Effect of a proparacaine 0.50%-sodium fluorescein 0.25% mix and contact ultrasound pachymetry on central and midperipheral corneal thickness measured by noncontact optical pachymetry. [2011.05]
PURPOSE: To assess the effect of a combination of proparacaine 0.50%-sodium fluorescein 0.25% and ultrasound (US) pachymetry on central and midperipheral corneal thickness. SETTING: School of Optometry and Vision Sciences, Cardiff University, Cardiff, Wales, United Kingdom... CONCLUSIONS: Ultrasound pachymetry combined with proparacaine 0.50%-sodium fluorescein 0.25% caused a small (<10 mum) but significant amount of corneal swelling on average. Because the effect on corneal thickness may be greater than -10 to +30 mum in individual cases, clinicians should avoid contact procedures before obtaining topographic maps of corneal thickness using scanning-slit and Scheimpflug devices. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Ophthetic (Proparacaine Ophthalmic)
Accu-Chek Combo in Young Patients [Not yet recruiting]
This is an open, prospective, descriptive study aiming to evaluate the change in treatment
satisfaction of primary care givers of young children who use the Accu-Chek Combo System.
Patients will routinely be scheduled and start their therapy with the Accu-Chek Combo System
on visit 1. Twelve weeks later the final acquisition of data will occur. Diabetes Treatment
Satisfaction Questionnaires (DTSQ) will be completed at baseline and after 12 weeks, a
distinct acceptance questionnaires will be completed at final visit. In addition, Diabetes
related therapeutic information will be collected and data about the use of the device
components will be downloaded from the Accu-Chek Combo System
Proparacaine and Mydriatic Eye Drops [Recruiting]
In this study, we will be evaluating whether premedication with an anesthetic eye drops
leads to a decreased sensation of pain when given dilating eye drops prior to eye
examinations to evaluate for retinopathy of prematurity in neonatal intensive care unit
Clinical Assessment of an in-Patient Glucose Monitoring System (Accu-Chek Inform Cobas IT 1000) [Completed]
The principal objective of this single-center 2-period study is to evaluate the glycemic
control of in-patients in 3 hospital departments (Diabetology, Cardiology and Pulmonary Care)
as the rate of capillary blood glucose measurements within a pre-define target range, and to
compare results during the period I (warning of the Accu-Check Inform glucose meter on
glucose levels not activated) and period II (warning activated).
Proparacaine vs Placebo for Corneal Injuries [Completed]
Introduction: Traumatic injuries to the outer covering of the eye (the cornea) are a common
emergency department complaint. They cause significant patient distress including pain, loss
of sleep and missed work days. There is currently no accepted, uniform approach to pain
management in this patient population. Emergency medicine and ophthalmology texts state that
prolonged use of medications that anesthetize the cornea is not recommended. Several recent
publications in the ophthalmology literature show that the outpatient use of dilute local
anesthesia in patients after eye surgery is a safe and effective method of pain control. In
this study, we used Proparacaine (a local anesthetic), in a similar manner, for the
outpatient emergency department management of traumatic corneal injuries.
Methods: We performed a clinical trial on a sample of adult patients presenting with
traumatic corneal injuries to two university affiliated emergency departments in London,
Patients providing signed informed consent to participate in the study received a vial of
clear liquid that contained either Proparacaine or plain water (placebo), a pain log, topical
antibiotics and oral Acetaminophen (Tylenol) with Codeine for breakthrough pain.
Patients were instructed to use the "study drug" on an "as-needed" basis for the next seven
days. Patients completed a pain scale describing their discomfort immediately prior to, and
five minutes after self-administration of the study drug. All patients were followed closely
in an ophthalmology outpatient clinic on Days 1, 3 and 5 after presentation to the emergency
department. At the last ophthalmology clinic visit, the patients' pain logs were collected.
The protocol was approved by the Research Ethics Board for Health Sciences Research
Involving Human Subjects at the University of Western Ontario.
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study [Recruiting]
COMPASS is a status and intervention study for the self-monitoring of blood glucose (SMBG)
in type 2 diabetic patients with insulin treatment. This multi-centre, open-label
prospective study will assess the use and frequency of SMBG and blood glucose control and
its influencing factors with the help of Accu-Chek Integra glucometer. Patients with type 2
diabetes mellitus who have received more than 3 months of insulin therapy are eligible to
participate in this study. The anticipated duration of the study is 6 months.